Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Present Market Standing of Moderna Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1. RSI indicators show the stock to be may be approaching oversold. Earnings ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...